Sunbelt Securities’s Denali Therapeutics DNLI Stock Holding History

Sunbelt Securities’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$422	Hold	22	–	–	﹤0.01%	2339
2025 Q4	$363	Hold	22	–	–	﹤0.01%	2306
2025 Q3	$319	Buy	+22	New	+$316	﹤0.01%	2335

Other funds holding DNLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sunbelt Securities's DNLI Position: Q1 2026 in Review

Sunbelt Securities held its Denali Therapeutics (DNLI) position steady in Q1 2026 at 22 shares worth $422. The position accounts for ﹤0.01% of the portfolio, ranked #2339.

Sunbelt Securities first reported a position in DNLI in Q3 2025 and has held it in 3 quarters since. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Sunbelt Securities held 22 shares of Denali Therapeutics worth $422 as of Q1 2026.
Sunbelt Securities left its Denali Therapeutics share count unchanged in Q1 2026.
Denali Therapeutics made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2339 holding.
Sunbelt Securities first reported a position in Denali Therapeutics in Q3 2025 and has held it in 3 quarters since.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.